Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

Nivolumab is a fully human monoclonal antibody that inhibits programmed cell death‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non‐s...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:CPT Pharmacometrics Syst Pharmacol
Glavni autori: Zhang, Jason, Sanghavi, Kinjal, Shen, Jun, Zhao, Xiaochen, Feng, Yan, Statkevich, Paul, Sheng, Jennifer, Roy, Amit, Zhu, Li
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6930858/
https://ncbi.nlm.nih.gov/pubmed/31710163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12476
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items